Genotropin
(Somatropin)ApprovedSmall molecule
EMD SeronoSomatropin is a synthetic human growth hormone used to treat growth hormone deficiency in children and adults, helping them grow taller and develop normally. It's also used to treat certain conditions like Turner syndrome and muscle-wasting diseases.[2] Genotropin is currently approved and in use across 65 indications[4].[1]
Genotropin is one of 1012 small molecule programs targeting Insulin resistance. It is currently in Approved.
65
Indications
123
Total Trials
4
Active Trials
1,011
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 65 indications
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Genotropin
EMD SeronoApproved
Voltaren
CCerimon Pharmaceuticals
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Paracetamol
GSKPreclinical
Lunesta
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Botox
AbbViePreclinical
Lornoxicam
PPOZEN
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Growth35 trials
Show 32 more trials
Growth Hormone to Increase Immune Function in People With HIV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00071240·22 enrolled
Clinical Trial of Growth Hormone in MPS I, II, and VI
Terminated·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2/3·NCT00748969·2 enrolled
Growth Hormone Treatment of Children With HIV-Associated Growth Failure
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006143·102 enrolled
Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00050921·60 enrolled
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
Active, not recruiting·—·Phase 2·NCT05382637·1 enrolled
Growth Hormone Deficiency24 trials
Show 21 more trials
Small for gestational age10 trials
Show 7 more trials
Turner syndrome6 trials
Short stature4 trials
30 more indications
Noonan syndrome3 trials
Adult3 trials
Safety and Efficacy3 trials
Insulin resistance2 trials
Children2 trials
Treatment2 trials
Observational Study2 trials
Labor1 trial
Alcoholic Fatty Liver Disease1 trial
End-Stage Renal Disease1 trial
Prader-Willi syndrome1 trial
Osteoarthritis1 trial
Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)
Recruiting·—·Phase 1/2·NCT07036003·34 enrolled
Tendinopathy1 trial
Trial1 trial
X-linked hypophosphatemic rickets1 trial
Achondroplasia1 trial
Tibia Fracture1 trial
Renal insufficiency1 trial
Ovarian1 trial
The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders
Unknown status·—·Phase 2/3·NCT05900661·300 enrolled
Single Dose1 trial
Acceptability1 trial
Adult Growth Hormone Deficiency1 trial
Unspecified5 trials
Regulatory
FDA Approval Timeline[5]
Oct 16, 1986
HUMATROPE
BLA BLA019640
May 25, 1995
ZOMACTON
BLA BLA019774
Aug 24, 1995
GENOTROPIN
BLA BLA020280
Dec 29, 1995
NUTROPIN AQ NUSPIN 10
BLA BLA020522
Aug 23, 1996
SEROSTIM
BLA BLA020604
Jun 20, 2000
NORDITROPIN
BLA BLA021148
May 30, 2006
OMNITROPE
BLA BLA021426
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Genotropin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Somatropin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Growth Hormone Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company